Sign In
Buy KALV
$26.95
+0.0100 (+0.0371%)
At Close: Jun 03, 2026
The Zacks Analyst Blog Highlights: ResMed, Ensign, DaVita, KalVista Pharmaceuticals and MEI Pharma
02:46pm, Tuesday, 18'th Feb 2020
The Zacks Analyst Blog Highlights: ResMed, Ensign, DaVita, KalVista Pharmaceuticals and MEI Pharma
Zoetis' (ZTS) Earnings and Revenues Beat Estimates in Q4
03:30pm, Thursday, 13'th Feb 2020
Zoetis (ZTS) beats on both earnings and sales in the fourth quarter of 2019.
New Covid-19 Cases Increase, 5 Defensive Stocks to Buy
03:03pm, Thursday, 13'th Feb 2020
Here are five defensive stocks that can shield your portfolio as Covid-19 continues to spread, instilling volatility in the stock market.
FibroGen's (FGEN) NDA for Roxadustat Accepted by the FDA
02:45pm, Wednesday, 12'th Feb 2020
The FDA accepts FibroGen's (FGEN) NDA for roxadustat for the treatment of anemia of chronic kidney disease in both non-dialysis-dependent and dialysis-dependent patients.
FibroGen's (FGEN) NDA for Roxadustat Accepted by the FDA
02:45pm, Wednesday, 12'th Feb 2020
The FDA accepts FibroGen's (FGEN) NDA for roxadustat for the treatment of anemia of chronic kidney disease in both non-dialysis-dependent and dialysis-dependent patients.
Two Big Pharma Alliances End in Nixed Deals. Here’s What Happened.
08:35pm, Tuesday, 11'th Feb 2020
Pfizer and Merck are each cutting ties with a smaller clinical-stage biotech after experimental drugs being developed under separate alliances fell short
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 10) AbbVie Inc (NYSE: ABBV ) Allergan plc (NYSE: AGN )
KalVista Pharmaceuticals Provides Update on Diabetic Macular Edema Programs
09:30pm, Monday, 10'th Feb 2020
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announc
Is KalVista Pharmaceuticals, Inc.'s (NASDAQ:KALV) CEO Overpaid Relative To Its Peers?
01:35pm, Wednesday, 05'th Feb 2020
In 2016 Andy Crockett was appointed CEO of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV). This analysis aims first to...
The Zacks Analyst Blog Highlights: Calavo Growers, Darling Ingredients, The Simply Good Foods Company, KalVista Pharmaceuticals and CareDx
The Zacks Analyst Blog Highlights: Calavo Growers, Darling Ingredients, The Simply Good Foods Company, KalVista Pharmaceuticals and CareDx
5 Defensive Stocks to Counter Coronavirus Scare
04:20pm, Monday, 03'rd Feb 2020
Here are five defensive stocks that can shield your portfolio from China's coronavirus that intimidates to weigh on the stock market.
5 Defensive Stocks to Counter Coronavirus Scare
04:20pm, Monday, 03'rd Feb 2020
Here are five defensive stocks that can shield your portfolio from China's coronavirus that intimidates to weigh on the stock market.
BioLineRx Concludes Recruitment in Pancreatic Cancer Study
04:44pm, Thursday, 23'rd Jan 2020
BioLineRx (BLRX) closes patient recruitment in the triple combination arm of the phase IIa COMBAT/KEYNOTE-202 study on Motixafortide to treat second-line metastatic pancreatic cancer.
Will KalVista Continue to Surge Higher?
10:29am, Thursday, 23'rd Jan 2020
As of late, it has definitely been a great time to be an investor in KalVista Pharmaceuticals.
